RecruitingNCT07397715

Association of Ultrasound Features of the Myometrium Suggestive of Adenomyosis and Clinical Symptoms

Association of Ultrasound Features of the Myometrium Suggestive of Adenomyosis and Clinical Symptoms (MUSA 3)


Sponsor

Swiss GO Trial Group

Enrollment

1,000 participants

Start Date

Mar 15, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this study/research is to assess the relationship between ultrasound features of the myometrium suggestive of adenomyosis and clinical symptoms of adenomyosis and to establish a reporting system for adenomyosis assessing disease severity. Consecutive pre- and perimenopausal symptomatic and asymptomicasymptomatic women with an uterus presenting for gynaecological ultrasound exams will be asked to participate in the study. Routine gynecologicalgynaecological ultrasound exams will be performed and study participants will fill out a questionnaire on their symptoms (if any) and bleeding pattern. There will be one visit and no interventions.


Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria3

  • Women of pre- and perimenopausal age presenting for gynaecologic ultrasound exam giving voluntary informed written consent.
  • Symptomatic and asymptomatic women
  • Patients with hormonal contraceptives and Hormone Replacement Therapy (HRT) can be included, but information will be noted.

Exclusion Criteria21

  • Missing written consent (study consent)
  • Any serious underlying medical, psychiatric or psychological condition, which may interfere with the patient's capacity of discernment.
  • Postmenopausal women
  • Pregnancy
  • History of pelvic urogynaecologic surgery (TVT, mesh surgery, etc.)
  • Malignancy or premalignancy of uterus/cervix
  • Prior myomectomy for FIGO 3-6 fibroids
  • Patients with coagulation disorders under current anticoagulation medication
  • Prior history of diagnosed intraabdominal adhesions (surgery)
  • Prior diagnosis of pelvic congestion syndrome
  • Psychiatric disease precluding a reliable estimation of pain
  • Prior surgery or treatment for deep infiltrating endometriosis
  • Acute other symptoms:
  • Urinary symptoms (dysuria, urgency, grade III stress incontinence)
  • Acute of chronic pelvic infection (cervicitis, endometritis, salpingitis, frozen pelvis)
  • Ovarian lesions
  • Sonographic signs of deep infiltrating endometriosis (DIE)
  • Intracavitary pathology (Fibroid 0-2, polyp, adhesions)
  • Retained products of conception
  • \>3 small fibroids below 2 cm in largest diameter FIGO 3-8 (i.e. the presence of three fibroids below 2cm is NOT considered an exclusion criterion)
  • Presence of any fibroid \>2cm.

Locations(3)

Medical University of Silesia

Sosnowiec, Poland

Hospital Universitari Dexeus

Barcelona, Spain

University Hospital Basel

Basel, Canton of Basel-City, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07397715


Related Trials